GMI Collaborates with Hospitals in Cork, Dublin and Derry
Dublin, Ireland, 8th December 2017 – Irish life sciences company Genomics Medicine Ireland Ltd. today announced a new cross-border research collaboration that aims to identify the genetic markers that can help diagnose, predict disease severity, and identify personalised treatments for patients with Multiple Sclerosis (MS).
People with MS are being invited to participate in the research, which is the most comprehensive genomic study of MS to be undertaken on the island of Ireland. The hospitals and research centres involved in the launch of this study are: Cork University Hospital in conjunction with the Clinical Research Facility Cork; St. Vincent’s University Hospital, Dublin; Tallaght Hospital, Dublin; and Altnagelvin Hospital in conjunction with the Western Health and Social Care Trust in Derry. Read More
Around 20,000 people in Ireland are diagnosed with inflammatory bowel diseases (IBD), chronic inflammatory gastrointestinal disorders primarily affecting adults in the prime of their life. There are two major forms of IBD, Crohn’s disease (CD) and Ulcerative Colitis (UC) which are life-long conditions for which there is currently no known cause or cure.
Onset is typically in childhood or in young adults so IBD has potential to impact educational performance and work productivity, as well as quality of life. Crohn’s Disease is associated with increased mortality in the Irish population and there is an increased risk of colon cancer to people with either Crohn’s disease or Ulcerative Colitis. Ireland has one of the highest rates of Colitis in the world.
Brother and sister Jack and Sarah McCaffrey are elite athletes, both having won an All-Ireland medal playing football for Dublin this September. Is it genetics that has led to the siblings’ prowess in sport? Read More
Transformational Research Aims to Unlock Keys to Lifelong Disorders including MS and IBD
Irish life sciences company, Genomics Medicine Ireland, is to collaborate with the Clinical Translational Research and Innovation Centre (C-TRIC), Western Health and Social Care Trust (Western Trust) and Ulster University to undertake comprehensive, population scale genomic research studies in Northern Ireland. Read More
Ireland’s first large-scale genomic study examining relationship between fitness and genetics
GMI has partnered with University College Dublin’s (UCD) Institute for Sport and Health to launch Ireland’s first large-scale research study into the role of genetics on fitness and health. Read More
GMI features in a BusinessInsider interview with GV Partner and GMI Board Member, Tom Hulme.
“Another life science company in the GV stable is Dublin-based Genomics Medicine Ireland, which has raised $40 million from GV and others to carry out genomic research across Ireland while examining the broader relationship between genetics, health, and disease.”
GMI’s research was recently featured in the Irish Times. The article highlighted the privacy protection measures GMI has put in place for study participants.
“The desire among those with a chronic complex disease and their families to find a cure is incredibly strong. This is the biggest impetus for people to participate in a research study — that by doing so they can help in some small way to help find better diagnosis, treatment and even cures”.
-Dan Crowley, CEO
GMI Co-Founder, Maurice Treacy, will be speaking this Thursday on the Precision Planet Panel at 11.30am PDT for the Precision Medicine Leadership Summit in San Diego, California. The geographically and experientially diverse group of leaders will explore the various challenges that governments, industry, and the nonprofit sector face when implementing the evolving technologies of precision medicine.
GMI Bioinformatician, Raony Guimaraes, was featured on GenomeWeb for his work alongside a team of colleagues from the Federal University of Minas Gerais in Brazil who developed an open-source software tool to enable researchers and clinicians to home in on disease-causing variants for Mendelian disorders in genomic data.
Their tool, called MendelMD, analyses and annotates exome or genome data, compares it against a number of databases, and filters it to identify a list of candidate disease-causing mutations.